NASDAQ:PRVL

Prevail Therapeutics (PRVL) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$23.00
$23.00
50-Day Range
$22.91
$23.20
52-Week Range
$9.02
$23.35
Volume
N/A
Average Volume
955,800 shs
Market Capitalization
$787.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PRVL stock logo

About Prevail Therapeutics Stock (NASDAQ:PRVL)

Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.

PRVL Stock News Headlines

The A.I. story nobody is telling you (Read ASAP)
There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...
The A.I. story nobody is telling you (Read ASAP)
There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...
Humanity must prevail in Gaza
Why Some Teams Fail And Others Prevail
See More Headlines
Receive PRVL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prevail Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2020
Today
4/24/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:PRVL
CIK
N/A
Fax
N/A
Employees
66
Year Founded
N/A

Profitability

Net Income
$-63,190,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.85 per share

Miscellaneous

Free Float
N/A
Market Cap
$787.66 million
Optionable
Not Optionable
Beta
1.59
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Asa Abeliovich M.D. (Age 56)
    Ph.D., Founder, Pres, CEO & Director
    Comp: $737.47k
  • Dr. Yong Dai Ph.D. (Age 49)
    Chief Technology Officer
    Comp: $450.62k
  • Dr. Jeffrey Sevigny M.D. (Age 51)
    Chief Medical Officer
    Comp: $593k
  • Dr. Brett Kaplan M.D. (Age 46)
    CFO & Sec.
  • Ms. Kira M. Schwartz
    Gen. Counsel
  • Ms. Emily Minkow (Age 37)
    Chief Bus. Officer
  • Dr. Franz F. Hefti Ph.D. (Age 72)
    Chief Devel. Officer

PRVL Stock Analysis - Frequently Asked Questions

How were Prevail Therapeutics' earnings last quarter?

Prevail Therapeutics Inc. (NASDAQ:PRVL) posted its quarterly earnings data on Friday, November, 13th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.09.

What other stocks do shareholders of Prevail Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prevail Therapeutics investors own include Sorrento Therapeutics (SRNE), Alector (ALEC), Gossamer Bio (GOSS), Editas Medicine (EDIT), Harpoon Therapeutics (HARP), Atreca (BCEL), Precision BioSciences (DTIL), Fulcrum Therapeutics (FULC), Inovio Pharmaceuticals (INO) and Stoke Therapeutics (STOK).

When did Prevail Therapeutics IPO?

Prevail Therapeutics (PRVL) raised $126 million in an IPO on Thursday, June 20th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

This page (NASDAQ:PRVL) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners